A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 28 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2018.
- 24 Apr 2016 Status changed from not yet recruiting to recruiting.
- 19 Mar 2015 New trial record